Director Abbhi retires; shareholders elect board, approve say-on-pay and auditor

BRAINSTORM CELL THERAPEUTICS INC.

Sankesh Abbhi retired from Board effective Dec. 14, 2021, prior to Annual Meeting; no disagreement.
All seven director nominees (Arbel, Almenoff, Polverino, Frenkel, Taub, Yablonka, Bairu) elected.
Non-binding advisory vote on executive compensation passed: 7,594,234 for, 981,374 against.
Ratification of Brightman Almagor Zohar & Co. as auditor approved: 19,042,561 for.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sankesh Abbhi

Director

BCLI · BRAINSTORM CELL THERAPEUTICS INC.

Effective: 2021-12-14
Filed: December 17, 2021, 6:59 PM ET

On December 14, 2021, Sankesh Abbhi retired from the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”), effective immediately prior to the commencement of the 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sankesh Abbhi retired as Director at BRAINSTORM CELL THERAPEUTICS INC..

Action: retired
Role: Director

Exact text from the filing

On December 14, 2021, Sankesh Abbhi retired from the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”), effective immediately prior to the commencement of the 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company.

View on SEC.gov

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-21-151224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.